In 1979 Steinberg and colleagues recognized a unique kindred with normotriglyceridemic hypobetalipoproteinemia (1979. J. . We have undertaken an intensive reexamination of this kindred and have studied 41 family members in three generations. In this family we document the presence of two distinct apo B alleles associated with low plasma concentrations of apolipoprotein (apo) B and low density lipoprotein (LDL) cholesterol and we trace the inheritance of these two alleles over three generations. One of the alleles resulted in the production of an abnormal, truncated apo B species, apo B-37. The other apo B allele was associated with reduced plasma concentrations of the normal apo B species, apo B-100.
Introduction
Apolipoprotein (apo)' B is a crucial structural protein of chylomicrons, very low density lipoproteins (VLDL) , and low density lipoproteins (LDL). Kane and co-workers (1) demonstrated the presence of two different apo B species in plasma. A high molecular weight form, apo B-l00, is made by the liver and is found in VLDL and LDL (1, 2) . A lower molecular weight form, apo B-48, is made by intestinal mucosal cells (3) , and is found 1. Abbreviations used in this paper: apo, apolipoprotein; NCM, nitrocellulose membrane.
The Journal of Clinical Investigation, Inc. Volume 79, June 1987, 1842-1851 in plasma chylomicrons and chylomicron remnants. Recently, our laboratory demonstrated that both apo B species are the product of a single gene (4) . The molecular basis whereby one gene yields both apoproteins is not yet understood.
When both forms of apo B are absent, as in recessive (or classical) abetalipoproteinemia, the concentrations of cholesterol and triglycerides in plasma are very low. Normal chylomicrons, VLDL, and LDL are not present in plasma, and the clinical syndrome is usually severe. Affected patients have fat malabsorption, retinitis pigmentosa, neurologic disorders, and acanthocytosis. Heterozygotes for this disorder reportedly have no chemical abnormalities and are asymptomatic (5, 6) . Recently, Gregg and co-workers (7) studied liver biopsies of two subjects with abetalipoproteinemia. They found normal to increased levels of apo B messenger RNA (mRNA) and substantial amounts of apo B in hepatocytes, yet virtually no apo B in plasma, suggesting the possibility of a defect in the secretion of apo B-containing lipoproteins.
In contrast to classical abetalipoproteinemia, familial hypobetalipoproteinemia is distinguished by its transmission as an autosomal dominant trait (6, 8, 9) . Subjects with the heterozygous form of familial hypobetalipoproteinemia are usually asymptomatic, and their LDL-cholesterol levels are about onehalf that of normal. Homozygotes have extremely low LDLcholesterol levels, and the clinical disorder is usually similar to that seen in patients with classical abetalipoproteinemia (6) .
In 1979, Steinberg and co-workers (10) described a unique kindred with familial hypobetalipoproteinemia. The proband, H.J.B., and several of his siblings had extremely low levels of apo B and LDL cholesterol (< 5% that of normal), yet they still had normal concentrations of plasma triglycerides. Although H.J.B. was completely asymptomatic, metabolic ward studies indicated the presence of mild fat malabsorption. LDL isolated from H.J.B.'s plasma had normal uptake when studied in cultured fibroblasts. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) ofhis LDL was said to show a normal apo B size.
Subsequently, Malloy and colleagues (1 1) reported the existence of a patient who also had extremely low levels of LDL cholesterol, but was normotriglyceridemic. Their patient was able to synthesize apo B-48, but not apo B-I00, and, as a result, the patient's plasma contained chylomicrons and chylomicron remnants, but no normal VLDL or LDL. Since then, there have been two other reports of patients who apparently synthesize apo B-48, but not apo B-100 (12, 13) . However, there have been no previous reports of any clinical entity associated with an abnormal apo B species in plasma (i.e., an apo B with an abnormal molecular weight).
Recently, our laboratory has undertaken a reexamination of the H.J.B. kindred. In the preceding article (14) , we characterized an abnormal apo B species, apo B-37, which is present in all of H.J.B.'s lipoprotein fractions. Here, we document that apo B-37 is present in eight other members ofthis kindred, all ofwhom also have hypobetalipoproteinemia. We analyze the transmission of familial hypobetalipoproteinemia over three generations in the H.J.B. kindred and demonstrate that the proband, H.J.B., and two of his siblings with markedly reduced plasma cholesterol levels, are actually compound heterozygotes for familial hypobetalipoproteinemia. One allele leads to the production of a truncated apo B species, apo B-37. The other abnormal allele results in the production of apo B-48 and apo B-I 00. However, this allele is associated with markedly reduced plasma concentrations ofapo B-I00. We trace the transmission ofboth ofthese abnormal alleles over three generations. This article and that preceding, document the presence ofan abnormal apo B species, apo B-37, thus providing the first example of a structural abnormality in apo B causing a distinct syndrome, in this case familial hypobetalipoproteinemia.
Methods
Plasma samples and lipoprotein isolation. Plasma was obtained from 41 members of the H.J.B. kindred. Nonfasting samples were obtained because we wanted to increase the yield ofthe triglyceride-rich lipoprotein fractions. One aliquot ofeach plasma sample was set aside for lipoprotein and apoprotein quantification. To the remainder ofthe plasma, multiple proteolytic inhibitors were added, as described (14) . These studies were approved by the Human Use Committee ofthe University ofCalifornia, San Diego. VLDL (d < 1.006 g/ml), intermediate density lipoprotein (IDL) (d = 1.006-1.025 g/ml), LDL (d = 1.025-1.063 g/ml), high density lipoprotein (HDL) (d = 1.063-1.21 g/ml), and lipoprotein-depleted plasma (d > 1.21 g/ml) were isolated under strictly sterile conditions using standard ultracentrifugation techniques (15) . Protein concentration of the lipoprotein fractions was determined with a modification of the Lowry technique, using a BSA standard (16 Antibodies. Three previously characterized monoclonal antibodies against apo B were utilized in the study: B3 (19, 20), MB19 (4, 19, 20, 21) , and MB47 (22) . In this study, B3 is designated MB3. MB3 and MB 19 both bind to epitopes in the amino-terminal region of apo B-100 (14) . Thus, both antibodies bind to the apo B-26 fragment and to the T4 thrombin-cleavage fragment of apo B-100 (14) . They also bind apo B-48 of normal chylomicrons and to the abnormal apo B species, apo B-37, contained in H.J.B.'s (and other affected family members') lipoproteins. MB47 binds an epitope in the carboxyl-terminal region of apo B-100 and thus binds to the T2 thrombin-cleavage fragment of apo B-100. It does not bind either apo B-48 of normal chylomicrons or apo B-37 of H.J.B. lipoproteins. Antibody MB19 detects a common form of genetic polymorphism in apo B; MB3 and MB47 do not. For radioimmunoassays (RIA), ascites was used as a source of antibody. For the double-label Western blot assays, we used immunopurified monoclonal antibodies, prepared from whole ascites using LDL-or protein A-Sepharose 4B columns, as previously described (20, 22) .
We also utilized a rabbit polyclonal antiserum generated against human LDL-apo B-100 (22) .
Apoprotein quantification. The total plasma apo B concentration was determined in a solid-phase, competitive RIA using antibody MB3, exactly as described (21 Although the absolute concentration of apo B in H.J.B. plasma was extremely low, we found that > 85% of the total apo B mass was apo B-37 and apo B-48 (14) . In the RIA, total apo B mass in plasma (expressed as milligrams per deciliter) was calculated using LDL-apo B-100 to form the standard curve. The protein concentration of the LDL-apo B-100 standard was determined chemically (16) . In affected members of the H.J.B. kindred, where a significant fraction of the total apo B is apo B-37, the true apo B mass in plasma will be overestimated by the RIA using MB3, which was calibrated using apo B-100 for the standard curve, (i.e., apo B-37 [203,000 mol wt]) presumably has the same immunoreactivity in the RIA as apo B-100 [550,000 mol wt]). In this report, we do not attempt to correct for this overestimation ofthe true apo B protein concentration in the subjects with apo B-37 because, in absolute terms, the concentration of apo B-37 in plasma was always quite small (< 12 mg/dl).
In selected members of the kindred, the apo B-100 concentration in plasma was determined in a solid-phase, competitive RIA using antibody MB47, which binds to apo B-100, but not apo B-48 or apo B-37.
Apo A-I concentration was determined in an immunoenzymometric assay, using monoclonal antibodies specific for apo A-I (24). The normal range for plasma apo A-I Fig. 1 . Nonfasting plasma lipoprotein concentrations as well as apo A-I and apo B concentrations for all family members studied are shown in Table I . H.J.B. and other affected members with hypobetalipoproteinemia are remarkable for the fact that despite extraordinarily low concentrations of cholesterol, they have relatively normal triglyceride levels (10) . Members of the family who had hypobetalipoproteinemia (an LDL-cholesterol concentration < 5% that of normal) are identified by a dark-highlighted circle or square in Fig. 1 .
Identification ofapo B-37 in the H.J.B. kindred
All lipoprotein fractions of all family members were studied by analytical SDS-PAGE. Apo B-37 was detected in the lipoproteins of H.J.B. and eight other family members spanning three generations. Family members whose lipoproteins contained apo B-37 are designated by an asterisk in Table I and in Fig. 1 . All subjects whose lipoproteins contained apo B-37 had hypobetalipoproteinemia.
In affected family members, apo B-37 was found in every density class, including HDL. In VLDL and IDL, apo B-100 and apo B-48 were also present. In subjects 1, 2, and 3, apo B-100, apo B-48, and apo B-37 were present in LDL. In subjects 13, 14, 18, 28, 32, and 34, apo B-100 and a small amount of apo B-37 (but not apo B-48) were present in LDL. Fig. 2 in the preceding article demonstrates the presence of apo B-37 in the VLDL of members of the kindred (subjects 2 and 18). In IiDL, apo B-37 was the only apo B species. Fig. 2 of this article demonstrates the presence of apo B-37 in the HDL of eight affected members of the kindred and the absence of apo B-37 in the HDL of two unaffected subjects. Fig. 3 demonstrates that apo B-37 was not found in the VLDL fractions of unaffected family members.
Apo B-37 was confined to the lipoprotein fraction ofplasma. In competitive RIAs using antibodies MB3, MB47, and the polyclonal antiserum, no apo B was detectable in the lipoproteindepleted plasma (d = 1.21 g/ml bottom fraction) of any of the 41 members of the H.J.B. kindred.
Analysis ofhypobetalipoproteinemia in the H.J.B. kindred Subjects 1, 2, and 3: the compound heterozygotes. In addition to H.J.B., two siblings, subjects 2 and 3, had extremely low LDL concentrations (Table I ). Although subject 3 had a nonfasting LDL concentration of 17 mg/ml, a prior fasting measurement was 4 mg/ml (I13), similar to those of H.J.B. and subject 2. Each of these three subjects had total plasma apo B concentrations < 10% of normal. All three had apo B-37 in their lipoproteins.
Whereas both children of H.J.B. (subjects 12 and 13) had hypobetalipoproteinemia, only one (subject 13) had apo B-37. All three children of subject 2 (subjects 14, 16, and 18) had hypobetalipoproteinemia; yet only two (subjects 14 and 18) had apo B-37. Subject 3 had two children (subjects 19 and 20); both had hypobetalipoproteinemia, but neither had apo B-37. Thus, all of the children of subjects 1, 2, and 3 had hypobetalipoproteinemia: three had apo B-37. Despite being younger, the LDLcholesterol and apo B levels in the seven hypobetalipoproteinemic children were actually higher than the extremely low concentrations found in their affected parents.
From an examination of these data, we postulated that the three siblings (subjects 1, 2, and 3) were actually compound heterozygotes for hypobetalipoproteinemia, whereas each oftheir children were heterozygotes. We hypothesized that subjects 1, 2, and 3 had one apo B allele, which resulted in reduced plasma concentrations of apo B-100, and a second apo B allele that yielded the abnormal apo B species, apo B-37 (which was also present in plasma in greatly reduced concentrations). Each of the offspring inherited one or the other abnormal allele and each had hypobetalipoproteinemia.
In order to further understand the inheritance of the apo B alleles, we utilized a common genetic polymorphism in apo B, This assay was used for subjects whose lipoproteins did not contain apo B-37. For subjects whose lipoproteins contained apo B-37, the binding of antibody MBl9 to apo B-100, apo B-48, and apo B-37 was studied using the double-label Western blot assay, as described in the Methods.
that the apo1B in plasma is normally produced in roughly equal morphism, equal amounts of apo B from each allele are present amounts from both apo B alleles (21, 25) . Consequently, in in plasma and hence the MB19/MB47 ratios are near 0.5 (25) . in all family members, except those whose lipoproteins contained apo B-37. The ratios are given in Table I , and the corresponding genotypes are indicated in Fig. 1 . In the nine family members whose lipoproteins contained apo B-37, the MBl9 binding pattern was determined using a double-label Western blot assay recently developed in our labApo B-1O00-0- 7) was isolated in the absence of proteolytic inhibitors. As a result, there is a prominent apo B-26 band (see preceding article). Lane 11 shows LDL from a control subject which was isolated in the absence of proteolytic inhibitors. Lane 12 shows chylomicrons isolated from the plasma of a normal subject.
oratory (4) . The advantage of this assay is that it allows a direct determination ofthe MBl9 binding pattern ofeach apo B species, as described in Methods. Thus, we could determine which MB 19 allele was associated with each of the apo B species, apo B-100, apo B-48, and apo B-37. In subjects 1, 2, and 3, antibody MB 19 bound weakly to apo B-100 of VLDL. In all three individuals, antibody MBl9 also bound weakly to apo B-48. Therefore, the normal apo B species, apo B-I00 and B-48, were the products of an apo B allele encoding for allotype MB 192. In contrast, in all three subjects, antibody MB19 bound very strongly to apo B-37, indicating that apo B-37 was the product of an apo B allele encoding for allotype MB l9 . The results of a representative double-label Western blot immunoassay for genetic analysis of subjects 1 and 2 are shown in Table II . Also included in the experiment shown in Table II was subject 18, one ofthe offspring of subject 2. The apo B-37 of subject 18 was also a product of a MB191 allele. The apo B-I00 and apo B-48 were the products ofa MB 19, allele inherited from the mother ofsubject 18. Results of the assays performed in all nine subjects whose lipoproteins contained apo B-37 are summarized in Table III. Subjects 1, 2, and 3 were therefore compound heterozygotes for hypobetalipoproteinemia and were heterozygotes for the MBl 9 polymorphism. One allele produced apo B-37, which reacted with antibody MBl9 with high affinity. In these individuals, the plasma concentration ofapo B-37 was < 8 mg/dl. We termed this allele "MB 191-37" to indicate that apo B-37 was always linked to the MB 19, polymorphism. The other apo B allele produced the apo B-100 and apo B-48, each of which reacted with antibody MBl9 weakly. The apo B-I00 concentrations in the plasma of subjects 1, 2, and 3 (determined by an RIA using the apo B-I00 specific monoclonal antibody MB47) were 0.375, 1.7, and 2.7 mg/dl, respectively. Thus, this allele resulted in a mark- Fig. 1 ).
edly reduced concentration of the normally occurning apo B species, apo B-100, resulting in hypobetalipoproteinemia (H). We have termed this hypobeta (H) allele "MB 192-H" to indicate that it was always linked to the MB 192 allele. Determination of the MB 19 binding pattern for each apo B species was made by the double-label Western blot immunoassay as explained in Methods. An example of one of the double-label assays is shown in Table II . In all nine family members with apo B-37, the apo B-100 and apo B-48 species were both products of a MB192 allele or both products of the MB1 91 allele. In all nine subjects, the apo B-37 species was a product of a MB191 allele. The families of the compound heterozygotes (subjects 1, 2, and 3) were studied in detail, and they proved to be highly informative. The wife of subject 1 was deceased. Both of his daughters (subjects 12 and 13) had hypobetalipoproteinemia.
Subject 12 had genotype MB192/MB192-H. The lipoproteins of subject 13 contained apo B-37 and her genotype was MB19,-37/MB 192. Thus, each child was a heterozygote for familial hypobetalipoproteinemia, having inherited one or the other of the father's abnormal apo B alleles. Despite the fact that the children were younger and female, their LDL levels were much higher than their father, a compound heterozygote.
Like subject 1, the genotype of subject 3 was MB191-37/ MB192-H. Her spouse's genotype was MB192/MB 192. Both children of subject 3 (subjects 19 and 20) had hypobetalipoproteinemia, but lacked apo B-37, and had genotypes MB192/ MB192-H.
The family of subject 2 was most revealing because it contained numerous family members in three generations. Subject 2 had three children, all ofwhom had hypobetalipoproteinemia. Two had apo B-37 (subjects 14 and 18); their genotypes were identical: MBl91-37/MB19, . Subject 16, whose lipoproteins did not contain apo B-37, had genotype MBl9,/MB192-H. All three children had LDL-cholesterol levels higher than that of their father. Subject 14 had 11 children; to date we have obtained plasma samples from nine. Subject 15, the wife of subject 14, was normolipidemic, and had genotype MB192/MB192. Because subject 14 was a heterozygote for hypobetalipoproteinemia, and because his wife was normolipidemic, one would predict that only children who inherited the MB191-37 allele should have hypobetalipoproteinemia. This was very clearly the case. Three offspring (subjects 28, 32, and 34) had hypobetalipoproteinemia and each had apo B-37. In each individual, the apo B genotype was MB19,-37/MB 192. The mean LDL-cholesterol level of unaffected offspring was 107, whereas it was 26 in those who had inherited apo B-37. Thus, the family of subject 2 demonstrates three-generation vertical transmission of the MB191-37 allele.
The family of subject 16, a son of subject 2, was Plasmas from two children of subject 9 were examined. As expected neither subject had hypobetalipoproteinemia. Two other siblings of H.J.B. had hypobetalipoproteinemia but did not have apo B-37 (subjects 5 and 7); their MBl9/MB47 ratios were 0.9-1.5. Like subjects 16, 37, 38, and 40, their proposed genotypes are MB191/MB1 92-H. Plasmas from several children of these subjects were examined. None had inherited the MB192-H allele.
Apo B concentrations in the heterozygotes for hypobetalipoproteinemia with apo B-37. In the six heterozygotes for the hypobetalipoproteinemia who had apo B-37 (subjects 13, 14, 18, 28, 32, and 34), apo B-100 concentrations measured in the competitive RIA that used antibody MB47 averaged 22.8 mg/ dl, significantly higher than the apo B-100 concentrations measured in the compound heterozygotes (subjects 1, 2, and 3). In the compound heterozygotes, the apo B-100 concentrations were all < 3.0 mg/dl. The higher plasma concentrations ofapo B-I00 in these heterozygotes are consistent with the presence of one normal apo B allele. In these same heterozygotes, the total apo B concentration in plasma, as measured by an RIA using antibody MB3 (which binds apo B-100, apo B-48, and apo B-37) averaged 32.5 mg/dl, higher than the measurement obtained in the RIA using MB47. This result is consistent with the presence of a small amount of apo B-37 (and apo B-48) in the plasma of these subjects.
Discussion
In the original report of Steinberg and co-workers (10), it was recognized that the H.J.B. kindred was unique in that some family members had markedly reduced LDL-cholesterol concentrations yet had normal triglyceride concentrations. However, the mechanism leading to the profound hypocholesterolemia in affected subjects was not elucidated. We have reexamined this unique kindred and in this article demonstrate that the hypobetalipoproteinemia can be accounted for by two distinct apo B alleles that can be traced over three generations. One of these alleles encodes for an abnormal apo B species, apo B-37. The apo B-37 allele was always associated with the MB191 polymorphism, and the allele was designated MB191-37. The other allele results in reduced plasma concentrations of the normal apo B species, apo B-100. This allele was always associated with the MB 192 polymorphism, and it has been designated MB1 92-H. In the first generation that we studied (H.J.B.'s generation), there were eight siblings. Three siblings (subjects 1, 2, and 3) were compound heterozygotes for familial hypobetalipoproteinemia; two (subjects 5 and 7) were heterozygotes for familial hypobetalipoproteinemia; and three (subjects 9, 10, and 1 1) had normal genotypes. The parents of the eight siblings are deceased. However, the mother is known to have had a fasting LDL-cholesterol concentration of 46 mg/dl (13) , a level typical of that found in the heterozygotes for hypobetalipoproteinemia. In that all eight siblings were heterozygous for the MB19 polymorphism, we propose that one parent had genotype MB191-37/MB191, and the other had genotype MB192/MB192-H.
Several investigators have reported that subjects with a heterozygous form of familial hypobetalipoproteinemia have a reduced risk for cardiovascular disease (8, 26) . Although our kindred is too small to address that question systematically, it is of interest that members of the H.J.B. kindred with hypobetalipoproteinemia reported no symptoms of atherosclerotic disease. The proband, H.J.B., one of the compound heterozygotes, is extremely healthy at the age of 75. His mother, who was almost certainly a heterozygote for hypobetalipoproteinemia, died at the age of 95, and one of the mother's siblings is known to have lived to be 105! In analyzing the genetics of hypobetalipoproteinemia in the H.J.B. kindred, we were fortunate to be able to utilize another polymorphism in apo B, the MB 19 polymorphism, as a genetic marker. The immunochemical basis ofthis extremely common polymorphism has been documented by our laboratory (21) . Recently, we demonstrated that the polymorphism is expressed in parallel in apo B-100 and apo B-48 (4) . The MB19 polymorphism itself has no apparent influence on plasma apo B or lipoprotein concentrations, at least in a Southern California population (25) . Our ability to detect the MB19 polymorphism enabled us to show that, in the three compound heterozygotes, apo B-37 was a product of an allele different from that of apo B-100 and apo B-48. In these three individuals, antibody MB19 bound to apo B-37 strongly, but bound to apo B-100 and apo B-48 weakly. In three generations of hypobetalipoproteinemic subjects with apo B-37, antibody MBl9 invariably bound apo B-37 with high affinity. Thus, in the limited number of family members studied, we observed no evidence for genetic recombination disrupting the linkage of these two markers on the apo B allele.
Equally intriguing, our data suggest that in this family the other allele resulting in hypobetalipoproteinemia is linked to the MB192 polymorphism. This allele, which we termed hypobeta allele (H), is associated with reduced plasma concentrations of the normal apo B species, apo B-100. Data obtained in three generations of the H.J.B. kindred strongly support the idea that this hypobeta allele is linked to the MB192 marker. We found no example of genetic recombination resulting in a disruption of the linkage between the MB 192 marker and hypobeta.
In the preceding article, we document that apo B-37 is not an artifact produced during lipoprotein isolation, and that apo B-37 is an amino-terminal fragment of apo B-100. It Although the apo B-37 allele was of immediate interest because its product, a truncated apo B species, had not been previously described, the other apo B allele in the H.J.B. kindred leading to hypobetalipoproteinemia, the hypobeta allele, is also quite interesting. This allele resulted in low plasma concentrations of the normal apo B species, apo B-100. Metabolic studies will be required to determine whether the low concentrations of apo B-100 are the result of enhanced degradation or reduced synthesis. Ifthe latter turns out to be the explanation, it is tempting to speculate that the defect in the hypobeta allele is in the promoter region of the apo B gene. Recently Myers et al. (27) have demonstrated that point mutations in the promoter region of a B-globin gene can lead to such reduced gene transcription. There are, of course, many other possibilities.
We are now beginning to study the molecular basis for the two abnormal apo B alleles in the H.J.B. kindred. These studies will be aided by the knowledge emerging from other labs on the complementary DNA (cDNA) sequence and the deduced amino acid sequence of apo B (28) (29) (30) (31) (32) (33) (34) . Studies to elucidate the structure and organization of the promoter region of apo B may also be quite helpful in the analysis ofthis family. We believe that careful biochemical and genetic analysis ofthis and other kindreds with hypobetalipoproteinemia will enhance our understanding ofthe structure and function of apo B as well as factors affecting regulation of its synthesis. Such investigations may even provide clues that will improve our understanding of the normal variations in plasma cholesterol concentrations in the general population.
